Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Cash: 2020-2025

Historic Change in Cash for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $24.8 million.

  • Lyell Immunopharma's Change in Cash rose 174.79% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 113.22%. This contributed to the annual value of -$38.6 million for FY2024, which is 274.88% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Change in Cash is $24.8 million, which was up 214.54% from -$21.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Change in Cash ranged from a high of $320.1 million in Q2 2021 and a low of -$170.9 million during Q3 2021.
  • Over the past 3 years, Lyell Immunopharma's median Change in Cash value was $6.7 million (recorded in 2024), while the average stood at $120,545.
  • Within the past 5 years, the most significant YoY rise in Lyell Immunopharma's Change in Cash was 781.89% (2023), while the steepest drop was 2,040.45% (2023).
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Change in Cash stood at -$99.7 million in 2021, then soared by 107.27% to $7.2 million in 2022, then slumped by 2,040.45% to -$140.6 million in 2023, then spiked by 104.77% to $6.7 million in 2024, then surged by 174.79% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, -$21.6 million for Q2 2025, and $14.7 million during Q1 2025.